NASDAQ:NBTX

Nanobiotix - NBTX Stock Forecast, Price & News

$3.45

0.00 (0.00%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $3.45
▼
$3.45
50-Day Range: $3.45
▼
$4.49
52-Week Range: $2.32
▼
$7.97

Volume: N/A
Average Volume: 1,942 shs
Market Capitalization: $120.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Nanobiotix (NASDAQ:NBTX) Stock

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Receive NBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.

NBTX Stock News Headlines

March 27, 2023 | finance.yahoo.com

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

March 27, 2023 | americanbankingnews.com

Nanobiotix (NBTX) to Release Quarterly Earnings on Tuesday

March 28, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

March 14, 2023 | finance.yahoo.com

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

December 27, 2022 | msn.com

Nanobiotix randomizes 1st patient in US in phase 3 head/neck cancer trial

December 27, 2022 | finance.yahoo.com

NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

December 21, 2022 | finance.yahoo.com

NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement

December 8, 2022 | finance.yahoo.com

Voting Rights and Shares Capital of the Company

March 28, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

November 15, 2022 | finance.yahoo.com

NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 14, 2022 | finance.yahoo.com

NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer

November 10, 2022 | finanznachrichten.de

Nanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update

November 10, 2022 | finance.yahoo.com

Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients

November 10, 2022 | finance.yahoo.com

NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer

November 9, 2022 | finance.yahoo.com

NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update

November 8, 2022 | finance.yahoo.com

NANOBIOTIX Voting Rights and Shares Capital of the Company

November 2, 2022 | finance.yahoo.com

NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3

November 1, 2022 | finance.yahoo.com

NANOBIOTIX to Present at the Jefferies London Healthcare Conference

October 27, 2022 | finance.yahoo.com

NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022

October 18, 2022 | finance.yahoo.com

NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank

September 28, 2022 | finance.yahoo.com

Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022

September 23, 2022 | finance.yahoo.com

Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022

September 22, 2022 | finance.yahoo.com

Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial

September 21, 2022 | finance.yahoo.com

Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

September 14, 2022 | seekingalpha.com

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

September 12, 2022 | finance.yahoo.com

Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024

September 7, 2022 | finance.yahoo.com

NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.

NBTX Company Calendar

Today: 3/28/2023
Next Earnings (Confirmed): 3/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NBTX
CUSIP: N/A
CIK: 1760854
Web: www.nanobiotix.com
Phone: 33-1-40-26-04-70
Fax: N/A
Employees: 98
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.71
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $3.13 million
Price / Sales: 38.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.91 per share
Price / Book: 3.79

Miscellaneous

Outstanding Shares: 34,880,000
Free Float: 33,673,000
Market Cap: $120.34 million
Optionable: Not Optionable
Beta: 0.14

Key Executives

Mr. Laurent Levy Ph.D. (Age 49)
Co-Founder, Pres of the Exec. Board & CEO
Comp: $585.36k

Mr. Bart Van Rhijn
CFO & Member of Exec. Board

Ms. Anne-Juliette Hermant M.A. (Age 48)
Chief People Officer & Member of Exec. Board
Comp: $304.33k

Prof. Para Prasad Ph.D. (Age 77)
Co-Founder and Member of Scientific Board

Mr. Earl J. Bergey Ph.d. (Age 67)
Co-Founder

Mr. Alain Dostie
Chief Operating Officer

Ms. Kathryn M. McNeil (Age 47)
Sr. VP of Investor Relations

Mr. Brandon Owens
VP of Strategic Marketing & Corp. Communication

Ms. Elsa Borghi
Head of Innovation & Drug Discovery

Ms. Sarah Gaubert
Head of Communication & Public Affairs Department

Key Competitors

View All Competitors

NBTX Stock - Frequently Asked Questions

How have NBTX shares performed in 2023?: Nanobiotix's stock was trading at $3.67 at the beginning of 2023. Since then, NBTX shares have decreased by 6.0% and is now trading at $3.45.
View the best growth stocks for 2023 here.
When is Nanobiotix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our NBTX earnings forecast.
How can I listen to Nanobiotix's earnings call?: Nanobiotix will be holding an earnings conference call on Wednesday, March 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-689-8573.
When did Nanobiotix IPO?: (NBTX) raised $95 million in an initial public offering on Friday, December 11th 2020. The company issued 6,500,000 shares at a price of $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO.

What is Nanobiotix's stock symbol?: Nanobiotix trades on the NASDAQ under the ticker symbol "NBTX."
How do I buy shares of Nanobiotix?: Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nanobiotix's stock price today?: One share of NBTX stock can currently be purchased for approximately $3.45.
How much money does Nanobiotix make?: Nanobiotix (NASDAQ:NBTX) has a market capitalization of $120.34 million and generates $3.13 million in revenue each year.
How can I contact Nanobiotix?: The official website for the company is www.nanobiotix.com. The company can be reached via phone at 33-1-40-26-04-70.

This page (NASDAQ:NBTX) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial